Payment overview · 2025
General Payments
$3,415.85
146 reported records · 31 companies
Healthcare provider profile · identity verified
Aixa E Rodriguez Vazquez, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · MANATI, PR · NPI 1336143064
Verified facts
What the public records show
CMS Open Payments records show Aixa E Rodriguez Vazquez, M.D. received $3,415.85 in general payments during 2025 across 146 reported records.
Janssen Pharmaceuticals, Inc accounted for 11.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 63 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ibrance, Jakafi.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 15599 records involving 6881 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Imbruvica by this doctor in 2024.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IBRANCE as an associated drug or biological on 54 records involving 52 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ibrance by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Prolia by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SPRYCEL as an associated drug or biological on 32 records involving 32 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Sprycel by this doctor in 2024.
Incyte Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JAKAFI as an associated drug or biological on 14854 records involving 6477 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Jakafi by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROMACTA as an associated drug or biological on 47 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Promacta by this doctor in 2024.
PBG PUERTO RICO LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IBRANCE as an associated drug or biological on 367 records involving 97 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ibrance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IBRANCE as an associated drug or biological on 11505 records involving 4934 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ibrance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $400.13 | 11.7% | 17 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $361.17 | 10.6% | 16 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $338.22 | 9.9% | 14 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $278.64 | 8.2% | 12 | 2025 |
| Tempus AI, Inc | Unresolved — no canonical attribution shown | $259.41 | 7.6% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $259.31 | 7.6% | 11 | 2025 |
| PBG PUERTO RICO LLC | Unresolved — no canonical attribution shown | $156.12 | 4.6% | 7 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $137.47 | 4.0% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $129.50 | 3.8% | 6 | 2025 |
| PUMA BIOTECHNOLOGY, INC. | Unresolved — no canonical attribution shown | $96.80 | 2.8% | 4 | 2025 |
| Eli Lilly Export S.A. Puerto Rico Branch | Unresolved — no canonical attribution shown | $96.44 | 2.8% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $82.80 | 2.4% | 4 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $76.13 | 2.2% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $72.75 | 2.1% | 3 | 2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $71.55 | 2.1% | 3 | 2025 |
| Caris MPI, Inc. | Unresolved — no canonical attribution shown | $68.35 | 2.0% | 3 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $50.52 | 1.5% | 2 | 2025 |
| Stemline Therapeutics Inc. | Unresolved — no canonical attribution shown | $49.90 | 1.5% | 2 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $46.89 | 1.4% | 2 | 2025 |
| pharmaand GmbH | Unresolved — no canonical attribution shown | $46.89 | 1.4% | 2 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $44.95 | 1.3% | 2 | 2025 |
| Rigel Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $43.42 | 1.3% | 2 | 2025 |
| Exelixis Inc. | Unresolved — no canonical attribution shown | $41.54 | 1.2% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.73 | 1.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.84 | 0.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.70 | 0.8% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $24.95 | 0.7% | 1 | 2025 |
| TAIHO ONCOLOGY, INC. | Unresolved — no canonical attribution shown | $24.53 | 0.7% | 1 | 2025 |
| Bayer Puerto Rico Inc. | Unresolved — no canonical attribution shown | $24.08 | 0.7% | 1 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $22.60 | 0.7% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $22.52 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,415.85 | 146 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $361.17 | 16 | 2025 |
Source payment records
|
|||||
| XT CDX Normalized: xt cdx |
Device | Tempus AI, Inc | $259.41 | 11 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Drug | ABBVIE INC. | $244.99 | 10 | 2025 |
Source payment records
|
|||||
| DARZALEX Normalized: darzalex |
Biological | Janssen Pharmaceuticals, Inc | $234.18 | 10 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC. | $146.21 | 6 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Pharmaceuticals, Inc | $142.55 | 6 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $129.50 | 6 | 2025 |
Source payment records
|
|||||
| CALQUENCE Normalized: calquence |
Drug | AstraZeneca Pharmaceuticals LP | $119.41 | 5 | 2025 |
Source payment records
|
|||||
| AKEEGA Normalized: akeega |
Drug | Janssen Pharmaceuticals, Inc | $118.23 | 5 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $116.10 | 5 | 2025 |
Source payment records
|
|||||
| Polivy Normalized: polivy |
Biological | Genentech USA, Inc. | $113.69 | 5 | 2025 |
Source payment records
|
|||||
| NERLYNX Normalized: nerlynx |
Drug | PUMA BIOTECHNOLOGY, INC. | $96.80 | 4 | 2025 |
Source payment records
|
|||||
| VERZENIO Normalized: verzenio |
Drug | Eli Lilly Export S.A. Puerto Rico Branch | $96.44 | 4 | 2025 |
Source payment records
|
|||||
| RUBRACA Normalized: rubraca |
Drug | TOLMAR, INC., pharmaand GmbH | $93.78 | 4 | 2025 |
Source payment records
|
|||||
| ELAHERE Normalized: elahere |
Drug | ABBVIE INC. | $93.23 | 4 | 2025 |
Source payment records
|
|||||
| WELIREG Normalized: welireg |
Drug | Merck Sharp & Dohme LLC | $92.49 | 4 | 2025 |
Source payment records
|
|||||
| KEYTRUDA QLEX Normalized: keytruda qlex |
Biological | Merck Sharp & Dohme LLC | $89.44 | 4 | 2025 |
Source payment records
|
|||||
| TALZENNA Normalized: talzenna |
Drug | PBG PUERTO RICO LLC | $83.94 | 4 | 2025 |
Source payment records
|
|||||
| XTANDI Normalized: xtandi |
Drug | PBG PUERTO RICO LLC | $83.94 | 4 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $76.13 | 3 | 2025 |
Source payment records
|
|||||
| MONJUVI Normalized: monjuvi |
Drug | Incyte Corporation | $76.13 | 3 | 2025 |
Source payment records
|
|||||
| IBRANCE Normalized: ibrance |
Drug | PBG PUERTO RICO LLC | $72.18 | 3 | 2025 |
Source payment records
|
|||||
| Odomzo Normalized: odomzo |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $71.55 | 3 | 2025 |
Source payment records
|
|||||
| YONSA Normalized: yonsa |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $71.55 | 3 | 2025 |
Source payment records
|
|||||
| BREYANZI Normalized: breyanzi |
Biological | E.R. Squibb & Sons, L.L.C. | $68.41 | 3 | 2025 |
Source payment records
|
|||||
| MI CANCER SEEK Normalized: mi cancer seek |
Device | Caris MPI, Inc. | $68.35 | 3 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | PBG PUERTO RICO LLC | $62.07 | 3 | 2025 |
Source payment records
|
|||||
| ZYNYZ Normalized: zynyz |
Drug | Incyte Corporation | $51.13 | 2 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $50.53 | 2 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $50.52 | 2 | 2025 |
Source payment records
|
|||||
| IMFINZI Normalized: imfinzi |
Biological | AstraZeneca Pharmaceuticals LP | $50.00 | 2 | 2025 |
Source payment records
|
|||||
| Orserdu Normalized: orserdu |
Drug | Stemline Therapeutics Inc. | $49.90 | 2 | 2025 |
Source payment records
|
|||||
| OPDUALAG Normalized: opdualag |
Drug | E.R. Squibb & Sons, L.L.C. | $48.46 | 2 | 2025 |
Source payment records
|
|||||
| ELIGARD Normalized: eligard |
Drug | TOLMAR, INC. | $46.89 | 2 | 2025 |
Source payment records
|
|||||
| TAGRISSO Normalized: tagrisso |
Drug | AstraZeneca Pharmaceuticals LP | $45.90 | 2 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | E.R. Squibb & Sons, L.L.C. | $45.67 | 2 | 2025 |
Source payment records
|
|||||
| EMRELIS Normalized: emrelis |
Drug | ABBVIE INC. | $45.36 | 2 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Drug | AstraZeneca Pharmaceuticals LP | $44.00 | 2 | 2025 |
Source payment records
|
|||||
| Gavreto Normalized: gavreto |
Drug | Rigel Pharmaceuticals, Inc. | $43.42 | 2 | 2025 |
Source payment records
|
|||||
| Rezlidhia Normalized: rezlidhia |
Drug | Rigel Pharmaceuticals, Inc. | $43.42 | 2 | 2025 |
Source payment records
|
|||||
| TAVALISSE Normalized: tavalisse |
Drug | Rigel Pharmaceuticals, Inc. | $43.42 | 2 | 2025 |
Source payment records
|
|||||
| KYPROLIS Normalized: kyprolis |
Drug | Amgen Inc. | $42.80 | 2 | 2025 |
Source payment records
|
|||||
| CABOMETYX Normalized: cabometyx |
Drug | Exelixis Inc. | $41.54 | 2 | 2025 |
Source payment records
|
|||||
| IMDELLTRA (AMG757) Normalized: imdelltra amg757 |
Biological | Amgen Inc. | $40.00 | 2 | 2025 |
Source payment records
|
|||||
| LUMAKRAS Normalized: lumakras |
Drug | Amgen Inc. | $40.00 | 2 | 2025 |
Source payment records
|
|||||
| XGEVA Normalized: xgeva |
Biological | Amgen Inc. | $40.00 | 2 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $32.73 | 1 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $29.84 | 1 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological | PFIZER INC. | $25.70 | 1 | 2025 |
Source payment records
|
|||||
| PEMAZYRE Normalized: pemazyre |
Drug | Incyte Corporation | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $24.95 | 1 | 2025 |
Source payment records
|
|||||
| Vonjo Normalized: vonjo |
Drug | SOBI, INC | $24.95 | 1 | 2025 |
Source payment records
|
|||||
| INQOVI Normalized: inqovi |
Drug | TAIHO ONCOLOGY, INC. | $24.53 | 1 | 2025 |
Source payment records
|
|||||
| LONSURF Normalized: lonsurf |
Drug | TAIHO ONCOLOGY, INC. | $24.53 | 1 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Puerto Rico Inc. | $24.08 | 1 | 2025 |
Source payment records
|
|||||
| Stivarga Normalized: stivarga |
Drug | Bayer Puerto Rico Inc. | $24.08 | 1 | 2025 |
Source payment records
|
|||||
| Itovebi Normalized: itovebi |
Biological | Genentech USA, Inc. | $23.78 | 1 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Pharmaceuticals, Inc | $23.40 | 1 | 2025 |
Source payment records
|
|||||
| JAYPIRCA Normalized: jaypirca |
Drug | Eli Lilly Export S.A. Puerto Rico Branch | $23.34 | 1 | 2025 |
Source payment records
|
|||||
| BRAFTOVI Normalized: braftovi |
Drug | ARRAY BIOPHARMA INC | $22.60 | 1 | 2025 |
Source payment records
|
|||||
| MEKTOVI Normalized: mektovi |
Drug | ARRAY BIOPHARMA INC | $22.60 | 1 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $22.52 | 1 | 2025 |
Source payment records
|
|||||
| Doptelet Normalized: doptelet |
Drug | SOBI, INC | $20.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| IBRANCE ibrance |
2025 | Ibrance | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JAKAFI jakafi |
2025 | Jakafi | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 15599 supporting records · 6881 recipient NPIs · example record 1201352838 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | IBRANCE open payments reported associated product |
CMS Open Payments — General Payments 54 supporting records · 52 recipient NPIs · example record 1228804288 |
Ibrance · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | SPRYCEL open payments reported associated product |
CMS Open Payments — General Payments 32 supporting records · 32 recipient NPIs · example record 1184390211 |
Sprycel · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Incyte Corporation Exact reporting entity; no affiliate inference |
2025 | JAKAFI open payments reported associated product |
CMS Open Payments — General Payments 14854 supporting records · 6477 recipient NPIs · example record 1225959940 |
Jakafi · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | PROMACTA open payments reported associated product |
CMS Open Payments — General Payments 47 supporting records · 47 recipient NPIs · example record 1200028032 |
Promacta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PBG PUERTO RICO LLC Exact reporting entity; no affiliate inference |
2025 | IBRANCE open payments reported associated product |
CMS Open Payments — General Payments 367 supporting records · 97 recipient NPIs · example record 1228798303 |
Ibrance · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | IBRANCE open payments reported associated product |
CMS Open Payments — General Payments 11505 supporting records · 4934 recipient NPIs · example record 1228794164 |
Ibrance · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Anastrozole | Anastrozole | 611 | 95 |
| Exemestane | Exemestane | 83 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 60 | 11 |
| Imbruvica | Ibrutinib | 56 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 41 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 33 | suppressed |
| Letrozole | Letrozole | 31 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 30 | suppressed |
| Prednisone | Prednisone | 30 | 11 |
| Hydroxyurea | Hydroxyurea | 29 | suppressed |
| Jakafi | Ruxolitinib Phosphate | 25 | suppressed |
| Dexamethasone | Dexamethasone | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 19 |
| Ibrance | Palbociclib | 18 | suppressed |
| Imatinib Mesylate | Imatinib Mesylate | 18 | suppressed |
| Brukinsa | Zanubrutinib | 16 | suppressed |
| Sprycel | Dasatinib | 16 | suppressed |
| Prolia | Denosumab | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Omeprazole | Omeprazole | 13 | suppressed |
| Promacta | Eltrombopag Olamine | 13 | suppressed |
| Bicalutamide | Bicalutamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,415.85 · 146 records | Janssen Pharmaceuticals, Inc | AKEEGA, BRAFTOVI, BREYANZI, CABOMETYX, CALQUENCE, DARZALEX, Doptelet, ELAHERE, ELIGARD, EMRELIS, EPKINLY, ERLEADA, Gavreto, IBRANCE, IMDELLTRA (AMG757), IMFINZI, INQOVI, Itovebi, JAKAFI, JAYPIRCA, KEYTRUDA, KEYTRUDA QLEX, KISQALI, KYPROLIS, LIBTAYO, LONSURF, LUMAKRAS, LYNPARZA, Lenvima, MEKTOVI, MI CANCER SEEK, MONJUVI, NERLYNX, Nubeqa, OJJAARA, OPDIVO, OPDUALAG, ORGOVYX, Odomzo, Orserdu, PADCEV, PEMAZYRE, Polivy, REBLOZYL, RUBRACA, RYBREVANT, Rezlidhia, SARCLISA, Stivarga, TAGRISSO, TALZENNA, TAVALISSE, Trodelvy, ULTOMIRIS, VENCLEXTA, VERZENIO, Vonjo, WELIREG, XGEVA, XT CDX, XTANDI, YONSA, ZYNYZ | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ibrance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error